Dirk Huebner
Overview
Explore the profile of Dirk Huebner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Studer G, Jeller D, Streller T, Huebner D, Glanzmann C
Adv Radiat Oncol
. 2024 Sep;
9(9):101566.
PMID: 39247539
Purpose: Lattice radiation therapy (LRT), a form of spatially fractionated radiation therapy, holds promise for treating large tumors. Despite its introduction in clinical practice around 2010, there remains limited information...
2.
Brockelmann P, McMullen S, Wilson J, Mueller K, Goring S, Stamatoullas A, et al.
Br J Haematol
. 2018 Sep;
184(2):202-214.
PMID: 30239982
First-line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron...
3.
Walewski J, Hellmann A, Siritanaratkul N, Ozsan G, Ozcan M, Chuncharunee S, et al.
Br J Haematol
. 2018 Sep;
183(3):400-410.
PMID: 30168134
Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 ...
4.
Connors J, Jurczak W, Straus D, Ansell S, Kim W, Gallamini A, et al.
N Engl J Med
. 2017 Dec;
378(4):331-344.
PMID: 29224502
Background: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods: We conducted an open-label, multicenter, randomized phase 3 trial involving patients...
5.
Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, et al.
EBioMedicine
. 2017 Nov;
25:50-57.
PMID: 29122619
Background: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead...
6.
Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, et al.
Blood
. 2017 Oct;
130(25):2709-2717.
PMID: 28974506
This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation...
7.
Zhou X, Mould D, Takubo T, Sheldon-Waniga E, Huebner D, Milton A, et al.
Br J Clin Pharmacol
. 2017 Sep;
84(1):35-51.
PMID: 28891222
Aims: This population pharmacokinetic analysis was conducted to describe quantitatively the regional differences and sources of interpatient variability on the apparent oral clearance of alisertib. Methods: A population pharmacokinetic analysis...
8.
Zhou X, Nemunaitis J, Pant S, Bauer T, Patel M, Sarantopoulos J, et al.
Invest New Drugs
. 2017 Aug;
36(2):240-247.
PMID: 28819760
Aims A primary objective of this study was to investigate the effect of single and multiple doses of alisertib, an investigational Aurora A kinase inhibitor, on the QTc interval in...
9.
Prince H, Kim Y, Horwitz S, Dummer R, Scarisbrick J, Quaglino P, et al.
Lancet
. 2017 Jun;
390(10094):555-566.
PMID: 28600132
Background: Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and...
10.
Gautam A, Zhu Y, Ma E, Lee S, Zagadailov E, Teasell J, et al.
Leuk Lymphoma
. 2017 Jun;
59(1):69-76.
PMID: 28583027
The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of...